The QualityStocks Daily Tuesday, May 28th, 2019

Today's Top 3 Investment Newsletters

QualityStocks (ALYE) +138.10%

StockMarketWatch (XRF) +72.75%

Penny Stock Titans (VIVK) +32.59%

The QualityStocks Daily Stock List

American Hotel Income Properties REIT LP (AHOTF)

MarketWatch, Stockhouse, OTC Markets, Dividend Channel, Marketbeat, Wallmine, Investors Hangout, Dividend Investor, Hotel News Resource, and Stockwatch reported earlier on American Hotel Income Properties REIT LP (AHOTF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

American Hotel Income Properties REIT LP (or AHIP) is a limited partnership created to invest in hotel real estate properties located in the U.S. The Company’s long-term goals are to build on its proven track record of successful investment, deliver reliable and consistent U.S. dollar denominated distributions to unitholders, and generate value via the continued growth of its diversified hotel portfolio. AHIP lists on the OTC Markets Group’s OTCQX. The Company is based in Vancouver, British Columbia.

An experienced management team consisting of proven hotel industry leaders, including award-winning entrepreneurs and executives, leads AHIP. The Company has three main business goals. One is to generate stable and growing cash distributions from hotel properties substantially in the U.S. The second is to enhance the value of its assets and maximize the long-term value of the hotel properties via active management. The third is to grow its asset base and increase its Adjusted Funds From Operations (AFFO) per Unit via an accretive acquisition program, participation in strategic development opportunities and improvements to the properties through targeted value-added capital expenditure programs.

At present, AHIP has 112 hotels. The Company is engaged in increasing its portfolio of premium branded, select-service hotels in larger secondary markets that have varied and stable demand. AHIP hotels operate under brands affiliated with Marriott, Hilton, IHG, Wyndham and Choice Hotels by way of license agreements.

Last month, AHIP announced that it exercised its option to buy out the ground lease associated with its Fairfield Inn & Suites White Marsh hotel in Baltimore, Maryland. It has completed the purchase of land for US$1.9 million plus closing costs. The expectation is that this acquisition will increase AHIP's cash flow by about US$165,000 annually, through the elimination of lease payments earlier expensed for this property.

Earlier this month, AHIP announced its financial results for the three months ended March 31, 2019. Mr. John O'Neill, AHIP Chief Executive Officer, said, "Our first quarter results demonstrate the hotels we renovated in 2018 are now commanding higher guestroom rates, generating substantially more food and beverage revenues, and driving higher margins. The six hotels that were renovated by the end of January collectively saw first quarter ADR grow 3 percent and revenue grow nearly 7 percent compared to the same period of 2018. The strong contribution from these newly updated hotels was partially offset by the impacts of ongoing renovations during the quarter, which compressed occupancy rates for our portfolio."

American Hotel Income Properties REIT LP (AHOTF), closed Tuesday's trading session at $5.28, up 0.96%, on 13,106 volume with 24 trades. The average volume for the last 3 months is 12,122 and the stock's 52-week low/high is $4.34/$7.22.

Origin House (ORHOF)

NetworkNewsWire, New Cannabis Ventures, Marketfy, The Seed Investor, NIC Investors, PotNetwork, Wallet Investor, Stockwatch, Pot Stock News, Trading View, Midas Letter, Profit Confidential, Investors Hub, and Insider Financial reported previously on Origin House (ORHOF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

A North American cannabis products and brands company, Origin House is a firm based in Ottawa, Ontario. The Company (previously known as CannaRoyalty Corp.) specializes in acquisitions. It is actively developing infrastructure to support the proliferation of its brands worldwide, first through its acquisition of Canadian retailer 180 Smoke. Origin House operates across key markets in the United States and Canada. Its strategic emphasis is on becoming a preeminent international house of cannabis brands. Origin House lists on the OTC Markets’ OTCQX.

The Company has a strong distribution network, bringing 50-plus brands to greater than 400 retailers. Origin House sees strong revenue from owned and distributed brands. The Company states that it is building a portfolio of California brands that will be in demand around the world. While seeing strong revenue from owned and distributed brands in California, its acquired brands build its position for wider growth.

Origin House's foundation is in California, where it delivers in excess of 130 branded cannabis products from 50-plus brands to the majority of licensed dispensaries. The Company’s brand development platform is operated out of five licensed facilities located throughout California, and provides distribution, manufacturing, cultivation and marketing services for its brand partners.

Today, 22 Capital Corp. (LFC-P. V) and Trichome Financial Corp. announced that 22 Capital and Trichome Financial received conditional approval from the TSX Venture Exchange for their announced amalgamation under the provisions of the Business Corporations Act (Ontario), which will result in a reverse take-over of 22 Capital by the shareholders of Trichome Financial. Presently a subsidiary of CannaRoyalty Corp. d/b/a Origin House, Trichome is a private corporation.

The Transaction, if completed, will constitute 22 Capital's "Qualifying Transaction" as such term is defined in Policy 2.4 of the Exchange. Each of Trichome Financial and Origin House exists under the laws of the Province of Ontario. Incorporated on September 18, 2017, Trichome Financial is a specialty finance company centered on providing flexible and creative capital solutions to the worldwide legal cannabis market.

Origin House (ORHOF), closed Tuesday's trading session at $8.4776, up 5.57%, on 139,320 volume with 473 trades. The average volume for the last 3 months is 282,573 and the stock's 52-week low/high is $3.18/$9.75.

Cyber Security 1 AB (CYBNY)

Penny Stock Hub, Stockhouse, Morningstar, Teletrader, Interactive Brokers,, GlobeNewswire, Dividend Investor, 4-Traders, YCharts, GuruFocus, GlobeNewswire, Seeking Alpha, and Trading View reported earlier on Cyber Security 1 AB (CYBNY), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Cyber Security 1 AB (CYBNY) is an international leader in Cyber Security. The Company provides cyber resilience solutions and conducts its operations through physical presences in Sweden, South Africa, the UK, Kenya, Germany, Austria, Turkey, Greece, Italy, the Ukraine and the United Arab Emirates (UAE). The Company formerly went by the name Cognosec AB (publ). It changed its name to Cyber Security 1 AB in July of 2018. OTCQX-listed, Cyber Security 1 AB is based in Stockholm, Sweden.

Providing governance, risk, and compliance cybersecurity solutions, Cyber Security 1 offers solutions for client and information systems audit, penetration testing, application security assessment, and security monitoring. In addition, the Company offers solutions for urgent incident response and crisis management, data leakage and loss prevention, as well as network security and management.

Cyber Security 1 has a growing worldwide footprint, an impressive client list, a flourishing mergers and acquisition (M&A) strategy and in 2019 a newly appointed Chief Executive Officer (CEO). The Company is entering its new phase with Mr. Nick Viney, its newly appointed CEO. Mr. Viney joined Cyber Security 1 after a successful 7-year career at McAfee. His resume also consists of several senior management positions at many of the world’s largest global technology companies, including Microsoft, Google, eBay and Arthur Andersen.

Cyber Security 1 AB announced this past March the signing of exclusive Heads of Terms of Agreement pursuant to the acquisition of IntaForensics. Since IntaForensics’ formation in 2006, the business has grown worldwide to provide the widest variety of Digital Forensic and Cyber Security Services from its England headquarters.

IntaForensics is one of the fastest growing Digital Forensic Services providers globally. It is one of a few organizations that possesses the prestigious ISO/IEC 17025 Laboratory Standard. Additionally, it is accredited to ISO/IEC 27001 and ISO 9001. The business is accredited by the PCI Security Standards Council as a Qualified Security Assessor and a PCI Forensics Investigator (QSA, PFI).

For Q1 2019, Cyber Security 1 achieved a 485 percent year-on-year increase in Revenue. The Company delivered the most successful Q1 in its history, with Revenue results of 19.6m EUR. Organic Revenue (excluding 2018 acquisitions) grew by 288 percent, from 3.35m EUR Q1 2018, to 13.03m EUR Q1 2019.

Cyber Security 1 AB (CYBNY), closed Tuesday's trading session at $1.21, even for the day, on 1,180 volume. The average volume for the last 3 months is 168 and the stock's 52-week low/high is $1.21/$5.00.

Vogogo, Inc. (VGGOF)

Penny Stock Hub, CryptoSwan, StockPulse, Stock Digest, Stockwatch, Stockhouse, Wallet Investor, Morningstar, Investors Hangout, Midas Letter, Wallmine, and OTC Markets reported earlier on Vogogo, Inc. (VGGOF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Vogogo, Inc. presently operates its cryptocurrency mining activities in the Province of Québec and the Company is Canada’s fastest growing miner. This includes mining for cryptocurrencies for its own account and within mining pools. Currently, the Company has about 23,000 Bitmain Antminer S9’s actively mining for its own account, producing roughly 295 Petahashes per second (PH/s) of hashing power. Vogogo lists on the OTC Markets Group’s OTCQB. The Company has its corporate office in Toronto, Ontario.

Vogogo, over the past 12 months, has increased its mining operations from 4,125 S9’s, which produced approximately 50 PH/s to approximately 23,000 S9’s and 295 PH/s. This represents greater than 450 percent growth.

Mr. Paul Leggett, Chief Operating Officer of Vogogo, recently said, “Our data centers are now at full capacity in terms of physical space with our 23,000 S9’s. Through our recent energy optimization efforts, we are now drawing less power even though we are running more machines. Currently, we are only drawing 33MW of a total available 36MW and are evaluating cost-effective options for the excess 3MW.”

On April 29, 2019, the Régie de l’énergie in Québec issued its decision for the blockchain file, providing certainty pertaining to electricity rates for Vogogo in Québec. The Regulator confirmed Vogogo’s industrial hydro electric rates (LG and M) from Hydro Quebec will not be increased.

Vogogo has developed two modern cryptocurrency mining facilities powered with low-cost, clean energy. The Company’s facilities were designed with the latest cryptocurrency mining data center techniques and optimizations. Its facilities have been designed with modern electrical and HVAC techniques for cryptocurrency mining.

Vogogo also develops hashrate optimization software and data center management software. Its proprietary software optimizes hashrate and its monitoring systems alert of any issues in the datacenter.

Vogogo’s mission is to build applications and services that are vital to the Bitcoin ecosystem and its stakeholders. The Company’s vision is to quickly improve the usability of cryptocurrencies and blockchain applications and speed up their adoption.

Vogogo, Inc. (VGGOF), closed Tuesday's trading session at $1.5535, up 29.46%, on 683 volume with 3 trades. The average volume for the last 3 months is 83 and the stock's 52-week low/high is $0.8977/$10.204.

Aly Energy Services, Inc. (ALYE)

Penny Stock Tweets, Stockwatch, Zacks, Stockhouse, Simply Wall St, Stockopedia, Marketbeat, Capital Network, Pink Investing, Market Exclusive and OTC Markets reported previously on Aly Energy Services, Inc. (ALYE), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Aly Energy Services, Inc., together with its subsidiaries, provides oilfield services to oil and gas exploration and production companies. The Company is a multi-faceted oilfield services enterprise. Its products and services include Solids Control and Surface Rental Equipment. Established in 2001, Aly Energy Services is headquartered in Houston, Texas. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Aly Energy Services and its subsidiaries provide equipment and services essential to the drilling and development of oil and gas resources. This includes mud delivery, solids control, as well as fluid management. Aly chiefly operates in Texas in the Permian Basin and Eagle Ford Shale, and in Oklahoma.

Fundamentally, Aly Energy Services is an oilfield manufacturing, rental and services company driven by fast-growing horizontal drilling activity in the North American shale plays. The Company serves an increasing number of oil and gas companies in every major North American Shale Play. Furthermore, Aly is pursuing acquisition opportunities to broaden its services and regional footprint. Regarding Solids Control, Aly Energy Services provides premier solids control equipment designed for closed loop systems through offering a customized solution to meet a customer’s specific needs. The Company features first-rate technology.

VFD (Variable Frequency Drive) technology allows for low amperage draw during start-up, reducing costs and adjustments during operation, enabling greater flexibility. The Company’s motor and rotating assembly are separate components making repair/replacement easy and enabling downtime to less than an hour.

Moreover, Aly Energy Services provides personnel at the customer's well site to operate the equipment, and also to rig-up/rig-down and haul the equipment to and from the customer's location. Pertaining to Surface Rental Equipment, its equipment includes centrifuges and auxiliary solids control equipment; mud circulating tanks of 400 and 500 barrel capacity; and auxiliary surface rental equipment, including portable mud mixing plants and containment systems.

Aly Energy Services, Inc. (ALYE), closed Tuesday's trading session at $2.50, up 138.10%, on 3,978 volume with 7 trades. The average volume for the last 3 months is 227 and the stock's 52-week low/high is $0.1341/$6.05.

Pulse Evolution Group, Inc. (DGLF)

Simply Wall St, Barchart, GlobeNewswire, Guru Focus, TMXmoney, Stockhouse, Street Insider, Morningstar, Seeking Alpha, InvestorsHub, OTC Markets, and Investors Hangout reported previously on Pulse Evolution Group, Inc. (DGLF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Pulse Evolution Group, Inc. is a top developer of hyper-realistic digital humans and characters for entertainment, mixed reality and artificial intelligence (AI). In August 2018, the Company acquired Evolution AI Corporation, a developer of digital humans as an ‘inter-Face’ of AI applications. This included its majority interest in Pulse Evolution Corporation (PLFX).

Pulse Evolution Group lists on the OTC Markets OTCQB. The Company has its corporate office in New York, New York. It formerly went by the name Recall Studios, Inc. It changed its name to Pulse Evolution Group, Inc. in February of this year.

Pulse engages in the development of human animation technology to enable AI platforms to interact with consumers in the relatable form of human faces and human characters. In addition, the Company engages in the development of hyper-realistic digital humans and computer-generated assets, which perform in live shows, virtual reality, augmented reality, holographic, 3D stereoscopic, Web, mobile, interactive, and AI applications. Furthermore, it engages in the storage, protection, as well as distribution of virtual facebanks.

Pulse Evolution Group concentrates on creating software and experiential applications that elevate the way consumers interact with content. Its primary strategy has been centered on the increasing market of Mixed Reality (virtual reality and augmented reality) with a portfolio of proprietary technology (including two patents pending) that is ready for market and scheduled for commercial introduction.

Today, Pulse Evolution Group announced the cash prepayment of its remaining, outstanding convertible debt. With cash prepayments of $1.6 million during 2018, and an additional $843,000 of prepayments so far this year, Pulse was able to prepay the entirety of high-risk convertible notes that would have entitled the holders of such notes to convert into the Company’s marketable common shares. Pulse Evolution’s prepayments were made before the noteholders vesting in the entitlement to exercise equity conversion rights. Pulse now has a zero balance of high-risk structured debt.


Pulse Evolution Group, Inc. (DGLF), closed Tuesday's trading session at $5.45, even for the day, on 58 volume with 2 trades. The average volume for the last 3 months is 642 and the stock's 52-week low/high is $3.29/$23.625.

Verra Mobility Corporation (VRRMW)

All Penny Stocks, Stock Trends, Penny Stock Hub, Whale Wisdom, Business Wire, Teletrader, Stock Consultant, Financial Tailor, Trade Ideas, and Symbol Surfing reported previously on Verra Mobility Corporation (VRRMW), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Verra Mobility Corporation concentrates on solutions that help the world move safely and easily. The Company accomplishes this by building safe cities, smart roadways and the connected systems that tie them together. It provides smart mobility technology solutions and services in the United States, Canada, and Europe. Verra Mobility lists on the OTC Markets. The Company has its corporate headquarters in Mesa, Arizona.

Verra Mobility works to understand new customers, regions and businesses, which will shape tomorrow’s smart mobility experiences. This is all in an effort to ensure more people worldwide reach their destination safely and easily. The Company seamlessly connects people across the smart mobility ecosystem to important data they require to improve and simplify administrative processes.

Verra Mobility offers big data and visionary solutions. This is to make roadways around the world more efficient. It offers Commercial Fleet Toll Management; Rental Fleet Toll Management; and Parking Solutions. Regarding Safe Cities, Verra Mobility helps make cities safer for everyone through integrating hardware, software, and data to inform and enforce moving violations and solve crime.

While the Company is leading to a new era of smart mobility, Verra Mobility continues to honor the heritage of its legacy brands. These comprise American Traffic Solutions (ATS), Highway Toll Administration (HTA), and Euro Parking Collection (EPC).

American Traffic Solutions (ATS) is a foremost provider of smart transportation solutions. These provide its customers with the highest level of convenience, safety, as well as value. The Company serves the nation’s largest fleets and rental car companies. ATS processes almost 50 million toll transactions and more than 1 million violations annually.

Highway Toll Administration (HTA) is a service provider to rental agencies and fleet operators across North America. It is a private company contracted by its clients to provide tolling and violation management solutions. HTA is not affiliated with any government agencies.

Euro Parking Collection (EPC) specializes in the identification, notification, and collection of unpaid traffic and public transport related fees, charges, and penalties issued to foreign registered vehicles (FRV) or persons throughout Europe. EPC currently works on behalf of greater than 450 issuing organizations in 15 European countries.

Verra Mobility Corporation (VRRMW), closed Tuesday's trading session at $4.54, even for the day, on 4,039 volume with 9 trades. The stock's 52-week low/high is $1.48/$5.00.

Monarch Gold Corporation (MRQRF)

InvestorsHub, The National Investor, Northern Vertex, Canadian Insider, Barchart, Junior Mining Network, The Street, 4-Traders, Mining & Energy, MarketWatch, Northern Miner, Morningstar, PR Newswire, GuruFocus, Private Capital News Wire, Stockhouse, YCharts, 24hgold, and Market Screener reported earlier on Monarch Gold Corporation (MRQRF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Monarch Gold Corporation is a developing gold producer listed on the OTC Markets. Its emphasis is on pursuing growth via its large portfolio of high-quality projects in the Abitibi mining camp in Quebec. The Company previously went by the name Monarques Resources, Inc. and Monarques Gold Corporation. Monarch Gold has its head office in Montreal, Quebec.

Monarch Gold owns almost 300 km² of gold properties. These include the Beaufor Mine, the Croinor Gold, Wasamac, McKenzie Break and Swanson advanced projects. Furthermore, the Company owns the Camflo and Beacon mills, and six promising exploration projects. In addition, Monarch offers custom milling services out of its 1,600 tonne-per-day Camflo mill.

Annual production at the Beaufor Mine is +20K ounces. The Beaufor Mine has strong drilling results. This includes 61.48 g/t Au over 3.9 m. There is excellent potential to increase the resource at Beaufor.

In late 2018, Monarch Gold reported positive results from the Feasibility Study (FS) prepared by BBA, Inc. for the Wasamac Gold project, situated 15 km west of Rouyn-Noranda, in Abitibi, Quebec. The results of the FS show that Wasamac is an economically viable project expected to be a low-cost producing mine. Also, the FS provides the basis for making a production decision. It also serves to totally support the permitting and financing processes.

Last week, Monarch Gold reported the third and last set of assay results from the 2018 diamond drilling program at its wholly-owned McKenzie Break gold project 25 kilometers north of Val-d'Or, close to its Camflo and Beacon mills. The program commenced in September 2018. It ended in December of 2018 with a total of 13,945 meters drilled in 61 holes.

The purpose of the program was to explore below the known lenses and on the periphery of the multi-vein Green and Orange zones. Assays were received for the last 20 holes totaling 5,052 meters of core.

Mr. Jean-Marc Lacoste, Monarch Gold’s President and Chief Executive Officer, said, "With the solid high-grade results obtained from our 2018 drilling program, we have upgraded the status of McKenzie Break as one of our prime advanced exploration projects. The program delivered beyond our expectations, enabling us to establish that the deposit remains open to the west, east, north and at depth and continues to hold excellent high-grade gold potential.”

Monarch Gold Corporation (MRQRF), closed Tuesday's trading session at $0.16, up 2.11%, on 139,500 volume with 17 trades. The average volume for the last 3 months is 32,122 and the stock's 52-week low/high is $0.159/$0.1084.

Timberline Resources Corp. (TLRS)

Amigo Bulls, Gold Investment Letter, Real Investment Advice, Zacks, MarketWatch, Street Insider, Market Screener, Equity Clock, InvestorsHub, Capital Cube, Marketbeat, and Barchart reported earlier on Timberline Resources Corp. (TLRS), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Timberline Resources Corp. is a gold exploration and development company. Its  operational focus is Nevada. The Company’s flagship Talapoosa Project is a partially permitted, open-pit, heap leach gold project with low capital and operating costs and strong economics. In addition, Timberline’s exploration efforts have been focused on its 23 square-mile Eureka land package. This is one of the largest remaining undeveloped gold properties in Nevada. OTCQB-listed, Timberline Resources is headquartered in Coeur d’Alene, Idaho.

The Company is refocusing its exploration efforts on advancing the Windfall and Lookout Mountain projects at its Eureka property. This is simultaneous with giving up its option to acquire the Talapoosa project. Regarding the Eureka land package, it includes Timberline’s Lookout Mountain project and a pipeline of earlier-stage projects that feature past gold production, historic gold estimates, and/or drill-indicated gold mineralization. Eureka is on the south end of Nevada’s Battle Mountain/Eureka Trend. 

Timberline continues to advance its Lookout Mountain and Windfall project areas at Eureka. It purchased a large block of patented and unpatented mining claims in 2012. These comprise mainly the entire Seven Troughs gold mining district near Lovelock in Pershing County, Nevada.

The purchased property package covers 4,100 acres. It consists of 64 patented and 238 unpatented lode mining claims, all which are under a long-term lease agreement, along with 162 additional unpatented lode mining claims.

Timberline Resources announced in 2018 that it closed on the acquisition of ownership interests in two Nevada gold-copper mineral properties in the Battle Mountain mining district in Nevada from Americas Gold Exploration, Inc. (AGEI). This acquisition includes the right to earn into existing Joint Venture agreements with McEwen Mining, Inc. at the Elder Creek Project (Elder Creek Joint Venture), and with Lac Minerals (USA) LLC, a wholly-owned subsidiary of Barrick Gold Corporation (LAC) at the Paiute Project (Paiute Joint Venture).

Recently, Timberline Resources announced consolidated financial results for its Q1 of fiscal year 2019 that ended December 31, 2018. The Company reported a Consolidated Net Loss of $0.5 million for the quarter ended December 31, 2018, including exploration expenditures of $272,000.

Timberline Resources’ President & Chief Executive Officer, Mr. Steve Osterberg, said, "We began Fiscal 2019 with continued exploration success at our Elder Creek Project in the Battle Mountain District with a very positive geophysical survey. We look forward to follow-up drilling on the priority anomaly, and expanding the survey coverage as we progress through the second quarter of 2019."

Timberline Resources Corp. (TLRS), closed Tuesday's trading session at $0.0757, up 15.40%, on 1,806 volume with 2 trades. The average volume for the last 3 months is 29,473 and the stock's 52-week low/high is $0.00009/$0.144.

Astro Aerospace Ltd. (ASDN)

Stockwolf, Stockhouse, Investors Hangout, 4-Traders, MarketWatch, Business Wire, Marketbeat, Stockopedia, Dividend Investor, Stockwatch, Barchart, Investors Hangout, YCharts, The Street, Penny Stock Hub, OTC Markets and Simply Wall St reported beforehand on Astro Aerospace Ltd. (ASDN), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Astro Aerospace Ltd. is the developer of the world’s most advanced autonomous, unmanned, and manned flying vehicles. It works to be at the vanguard of this disruptive aerial industry. The Company explores ways to apply its technology to worldwide challenges. These challenges include traffic congestion, pollution, and the overall stresses of daily life. Astro creates autonomous, eVTOL (Electric Vertical Takeoff and Landing) aerial vehicles and drones. Astro Aerospace has its corporate office in Lewisville, Texas. The Company lists on the OTC Markets Group’s OTCQB.

Astro Aerospace acquired the assets to VTOL industry leader, Passenger Drone. Astro Aerospace’s Passenger Drone is a state-of-the-art aerial transport vehicle. It is scheduled to improve urban mobility and enable passengers to arrive at their destination fast and safe.

Astro Aerospace’s drones do away with the need for gearboxes, water-cooling systems or aerodynamic steering flaps. The drones are outfitted with fiber optic technology.

Astro Aerospace’s in-house developed adaptive flight control algorithm keeps the ASTRO drone stable in most weather conditions, with minimal vibration. ASTRO Drones are a little bigger than a compact car. They can fit into most garages.

ASTRO was specifically designed with wide cabin glass for optimal comfort and a 360 degree surround view. The vehicle has a complete carbon body and is equipped with 16 individual rotors.

The ASTRO features Fiber Optic Internal Communications; Touch Flight Control; Adaptive Flight Control Software; and Encrypted Communication Channels. In addition, it features Field Oriented Motor Control; Fly-by-wire joystick; LTE (4G) network; and Glass Cockpit Avionics.

The ASTRO is suitable for operating in densely populated urban environments. It is an environmentally friendly solution. The design of its high-performance electric motor is to run quietly, fluidly, as well as completely emission-free.

This month, Astro Aerospace announced it has been accepted to participate in NASA’s UAM Grand Challenge commencing in 2020. The Company stated that its engineers and team are proud to be chosen to participate in the UAM Grand Challenge alongside “the best of the best" of the UAM community.

NASA is dedicated to supporting accessible air transport systems for passengers and cargo through working with the urban air mobility (UAM) community to identify and address the important challenges ahead. NASA will host a UAM ecosystem-wide challenge in 2020 for participants to execute system level safety and integration scenarios within a strong and relevant environment.

Astro Aerospace Ltd. (ASDN), closed Tuesday's trading session at $0.37, down 5.28%, on 178,838 volume with 85 trades. The average volume for the last 3 months is 126,981 and the stock's 52-week low/high is $0.31/$3.33.

Glance Technologies, Inc. (GLNNF)

Connecting Investor, Stock Invest, Wallet Investor, Trading View, InvestorsHub, Emerging Growth, Stockhouse, GuruFocus, Evergreen Caller, MarketWatch, InvestorsHub, and Insider Financial reported previously on Glance Technologies, Inc. (GLNNF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Glance Technologies, Inc. owns and operates Glance Pay. This is a streamlined payment system. Glance Pay transforms how smartphone users choose where to dine, order food and drink, settle bills, access digital receipts, earn premier rewards, and interact with merchants. With the Glance Pay mobile payment application (app), there is no set up or cancellation fees and no system integration or connections required. OTCQB-listed, Glance Technologies is based in Vancouver, British Columbia.

The Glance Pay mobile payment system consists of proprietary technology. This technology includes user apps available for free downloads in IOS (Apple) and Android formats, a merchant manager apps, a large-scale technology hosting environment with sophisticated anti-fraud technology, and very fast payment processing.

The Company offers targeted in-app marketing, social media marketing, customer feedback, in-merchant messaging, and custom rewards programs. The Glance Pay mobile payment app works for full service restaurants, quick serve restaurants (QSRs), retail, and more. Furthermore, the app features easy activation and training, easy automatic accounting and reconciliation, and quick payment deposits.

Glance Technologies’ intention is to apply components of its anti-fraud technology to cryptocurrencies. This is to lessen the risk associated with converting traditional currencies to and from cryptocurrencies. Glance is pursuing opportunities to license its earlier acquired BlockImpact cryptocurrency and blockchain platform as a white label solution.

Glance Technologies has launched its new Pay With Bitcoin feature. Pay With Bitcoin permits Glance Pay users to pair their cryptocurrency wallet with their Glance Pay account, and then buy Glance Dollars with Bitcoin. Glance Dollars represent a credit that can be spent quickly at participating merchants within the Glance Pay ecosystem.

Recently, Glance Technologies announced it officially launched its ‘Real-Time Bill™’ feature to the public at select locations. Numerous other locations are lined up for launch. ‘Real-Time Bill™’ is a pioneering new feature that allows users to view and pay their bill in real time directly from the Glance Pay™ App whenever they are ready to leave, without needing to wait for a paper bill.

This app identifies the user’s bill based on Quick Response (QR) codes or Near-field communication (NFC) tags at their table. The app accesses and settles the appropriate bill in real-time from the merchant’s point of sale (POS) system. ‘Real-Time Bill™’ considerably improves the experience for consumers. Moreover, it enables restaurants to turn their tables over much quicker. The result is greater revenue, lower staffing costs, as well as more satisfied customers.

Glance Technologies, Inc. (GLNNF), closed Tuesday's trading session at $0.1094, down 0.36%, on 166,211 volume with 32 trades. The average volume for the last 3 months is 177,393 and the stock's 52-week low/high is $0.074/$0.68.

Q BioMed, Inc. (QBIO)

Insider Financial, Proactive Investors, See Thru Equity Research, Market Screener, Penny Stock Tweets, Super Stock Screener, Business Insider, Tip Ranks, Stock News Now, Investing News, Simply Wall St, StockPicksNYC, and Barchart reported earlier on Q BioMed, Inc. (QBIO), and today we report on the Company, here at the QualityStocks Daily Newsletter. 

Q BioMed, Inc. is a commercial stage biomedical acceleration and development company. Its dedication is to licensing and acquiring biomedical assets across the healthcare spectrum. The Company’s commitment is to provide these target assets the strategic resources, developmental support, and expansion capital they require to ensure they meet their developmental potential, enabling them to provide products to patients in need. Q BioMed is based in New York, New York.

  The Company’s mission is to license and acquire unique life sciences assets from academia or small private companies. Q BioMed has numerous assets across a broad array of healthcare related products, companies, and sectors. These assets will undergo development to provide returns via organic growth or out-licensing, sale, or be spun out into new public companies. Q BioMed is concentrating on clinical stage and innovative products where the technical, regulatory, and commercial risks have been lessened or significant valuation modulations are pending.

  The Company has commenced production of Strontium-89 Chloride - a radiopharmaceutical indicated for the analgesic treatment of metastatic breast and prostate cancer bone pain. AB-Rated Strontium Chloride Sr89 Injection USP (Sr89) can be utilized in combination with, or to reduce the requirement for opiate based drugs, and also in combination with cancer therapeutic drugs. 

Q BioMed also is developing a unique molecule delivered in an easy-to-administer eye drop designed to repair the normal flow of fluid in the eye resulting in the decreasing of IOP (Intraocular Pressure) . The Company, together with its partner, Mannin Research, Inc, is the only company targeting this mechanism of action.

Q BioMed announced in November of 2018 that it entered into agreement to acquire the metastatic skeletal cancer palliation drug, Metastron™, from GE Healthcare. This agreement gives Q BioMed ownership of the brand, trademarks and market authorizations in 22 countries.

Q BioMed announced recently that its technology partner, Mannin Research, initiated a collaboration with McMaster University of Ontario, Canada. This collaboration is centered on ophthalmic drug delivery and formulation experiments for MAN-01, a first-in-class small molecule to treat Primary Open-Angle Glaucoma. Experiments will be conducted Dr. Heather Sheardown, a world renowned thought leader in ophthalmic biomaterials and drug delivery.

Uttroside-B is Q BioMed's liver cancer orphan drug candidate. The Company plans to complete pre-clinical work and prepare IND Proof of Concept Studies in the First Half of 2019 then file an IND in Q3 of 2019.

QBM-001 is the Company’s potential orphan drug treatment for young children and toddlers who are on the autism spectrum and are minimally verbal or non-verbal. Q BioMed is very hopeful that this therapy, consisting of very safe and well-known active ingredients, can make a major difference for these children and families. It looks forward to the completion of formulation and manufacturing by the end of Q2 2019 and a subsequent filing of an IND. The green light will permit it to commence a relatively short pivotal clinical trial of QBM-001 in Q3 2019.

Q BioMed’s commitment is to to growing and expanding the reach of its cancer palliation drugs. Its belief is that Metastron has significant untapped potential in expanded cancer therapeutic indications.

Q BioMed, Inc. (QBIO), closed Tuesday's trading session at $1.63, up 3.16%, on 9,165 volume with 24 trades. The average volume for the last 3 months is 46,791 and the stock's 52-week low/high is $0.89/$3.65.

Abattis Bioceuticals Corp. (ATTBF)

Greenbackers, Promotion Stock Secrets, InvestorIntel, Stockgoodies, Cannabis Financial Network News, PennyStocks24, CFN Media Group, Goldman Small Cap Research, and Information Solutions Group reported previously on Abattis Bioceuticals Corp. (ATTBF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Abattis Bioceuticals Corp. is a life sciences and biotechnology company based in Vancouver, British Columbia (BC). The Company aggregates, integrates and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. It has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. Abattis Bioceuticals also has an operations office in Langley, BC.

The Company’s brands include Vergence Naturals™. Additionally, Abattis is working to acquire exclusive intellectual property (IP) rights to agricultural technologies to be utilized in the extraction and processing of botanical ingredients and compounds.

The Company has, through its operations and wholly-owned subsidiaries, a broad array of capabilities. These include cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal marijuana markets in North America.

Abattis Bioceuticals has a 90 percent ownership interest in Gabriola Green Farms, Inc. Gabriola is a BC company. Gabriola has applied for a license to produce (LP) under the Access to Cannabis for Medical Purposes Regulations (ACMPR) on Gabriola Island, one of the gulf islands in the Strait of Georgia off the coast of BC. Currently, Gabriola has plans for an approximately 26,000 square-foot production facility to produce medical-grade marijuana located on 18 acres in the agricultural land reserve on Gabriola Island, BC.

Abattis is continuing its development work on a hemp-infused cannabinoid-rich, THC-free craft beer with Faculty Brewing Co. It is also continuing its development work on nanoemulsified and liposomal platforms for transmucosal delivery of cannabinoid-rich hemp oil with the University of British Columbia.

Abattis Bioceuticals has an investment in XLABS Therapeutics (ONT), Inc. Abattis and XLABS will be launching a new cannabis laboratory in Belleville, Ontario, to serve Ontario’s increasing cannabis sector.

This past November, Abattis Bioceuticals announced that it acquired Select Strains. Select Strains has a portfolio of greater than 140 laboratory-tested craft cannabis strains. Abattis hopes to leverage these via licensing arrangements, clone fulfillment, tissue culture and strain patenting services and ultimately through its late-stage ACMPR licensed producer applicant, Gabriola.

This month, Abattis Bioceuticals announced that, further to its new release dated December 7, 2018, it entered into a definitive share exchange agreement with 1157016 B.C. Ltd., d/b/a NutriVida, a private arm’s length company, whereby Abattis will acquire 100 percent of the issued and outstanding common shares of NutriVida. NutriVida has been well-known in the fertilizer and cultivation industry for the past 25 years. It has extensive knowledge and experience in researching, innovating, manufacturing, and selling all-natural, bio-safe, fertilizers and plant nutrients.

Abattis Bioceuticals Corp. (ATTBF), closed Tuesday's trading session at $0.0349, up 5.76%, on 462,735 volume with 47 trades. The average volume for the last 3 months is 606,565 and the stock's 52-week low/high is $0.017/$0.1919.

Acura Pharmaceuticals, Inc. (ACUR)

CRWEWallStreet, PennyToBuck, StreetInsider, Marketbeat,  SmarTrend Newsletters, Wall Street Resources, PennyOmega,  PennyStocks24,  Penny Stock Rumble, The Street, BestOtc, BUYINS.NET,  CRWEFinance, StockHotTips, and DrStockPick  reported on Acura Pharmaceuticals, Inc. (ACUR), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Acura Pharmaceuticals, Inc. is a specialty pharmaceutical company innovating abuse deterrent drugs. It engages in the research, development, and commercialization of product candidates intended to address medication abuse and misuse,  utilizing its proprietary LIMITx™, AVERSION®, and IMPEDE® Technologies. OTCQB-listed, Acura Pharmaceuticals is based in Palatine, Illinois.

The patented LIMITx technology works by neutralizing stomach acid with buffering ingredients as increasing numbers of tablets are swallowed. It relies on stomach acid to play a role in the release and subsequent systemic absorption of the active ingredient from micro-particles contained in the tablets.

The intention of the  LIMITX™ Technology is to address an oral Excessive Tablet Abuse (ETA) or accidental consumption of multiple tablets and provide a margin of safety during accidental over-ingestion of tablets. Additionally, LIMITX™ is expected to exhibit barriers to abuse by snorting and injection. LTX-04 is Acura’s lead development candidate employing its novel LIMITx™ technology.

AVERSION® Technology is a patented composition of commonly used active and inactive pharmaceutical ingredients providing abuse deterrent features and benefits for orally administered pharmaceutical drug products. The intention of AVERSION® Technology opioid analgesic product candidates is to provide effective relief from pain. This is while discouraging common methods of pharmaceutical product misuse and abuse.

OXAYDO® (oxycodone HCl immediate-release tablets), which incorporate the AVERSION Technology, is Food and Drug Administration  (FDA) approved and marketed in the  United States by Acura’s partner Egalet Corp. 

The IMPEDE® Technology platform is an advanced polymer matrix. It is used in NEXAFED®,  Acura Pharmaceuticals’ pseudoephedrine (PSE) tablet product, to limit or disrupt the extraction of PSE from tablets for conversion into the illicit drug methamphetamine. 

  NEXAFED® and NEXAFED® Sinus are pseudoephedrine containing products that use the IMPEDE Technology. They are marketed in the United States by Acura Pharmaceuticals’ partner MainPointe Pharmaceuticals.

This month, Acura Pharmaceuticals announced financial results for the three and six months ended June 30, 2018. Acura reported a Net Loss of $2.8 million or $0.13 per diluted share for the six months ended June 30, 2018, versus a Net Loss of $1.7 million or $0.15 per diluted share for the same period in 2017. For the Q2 2018, it reported a Net Loss of $1.3 million or $0.06 per diluted share versus a Net Loss of $2.2 million or $0.18 per diluted share for the same period in 2017.

Acura Pharmaceuticals, Inc. (ACUR), closed Tuesday's trading session at $0.269, up 16.96%, on 4,100 volume with 3 trades. The average volume for the last 3 months is 4,255 and the stock's 52-week low/high is $0.0601/$0.479.

The QualityStocks Company Corner

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) (the “Company” or “PLUS”), one of California’s top edibles brand and manufacturer by market share according to BDS Analytics, today announced its expansion into the Nevada market, its first market outside of California. PLUS has entered into a definitive agreement to partner with TapRoot Holdings Inc. (“Taproot”), a vertically integrated cannabis company operating cultivation and manufacturing facilities in Las Vegas, Nevada. Also today, NetworkNewsWire released a report on the company detailing how Plus Products’ newest addition to its product family — Create sour blueberry low-calorie gummies —is infused with hybrid flower and contains 5.0mg of THC. Moreover, the gummies are gluten-free and made with kosher ingredients. Additionally, the company was featured in the 420 with CNW by CannabisNewsWire. Banking associations from all the 50 states across the U.S. have written a letter to the Senate Banking Committee to pass and advance the bipartisan bill before it seeking to protect financial institutions from federal penalties for doing business with licensed marijuana businesses. In their letter delivered on April 20, the state banking associations observed that forcing cannabis businesses to operate on a cash-only basis exposes the businesses, their employees and the public to serious safety risks.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed the day's trading session at $3.531, off by 1.09%, on 97,568 volume with 166 trades. The average volume for the last 3 months is 76,455 and the stock's 52-week low/high is $2.81/$6.008.

Recent News

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced that combining Lexaria's DehydraTECH(TM) delivery technology with generic nanotech techniques has been proven to deliver 1,137% more cannabidiol ("CBD") into animal brain tissue following oral ingestion than certain existing industry formulations. To view the full press release, visit:

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $0.9744, up 9.48%, on 61,160 volume with 81 trades. The average volume for the last 3 months is 109,008 and the stock's 52-week low/high is $0.75/$2.43.

Recent News

Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P)

The QualityStocks Daily Newsletter would like to spotlight Nabis Holdings (OTC: INNPF).

Innovative Properties Inc. d/b/a Nabis Holdings (CSE: NAB; OTC: INNPF; FRA: 71P) (“Nabis Holdings” or the “Company”), a leading Canadian investment company, with specialty investments in assets across multiple divisions of the cannabis sector, is pleased to announce that further to its news release dated May 6, 2019, the effective date for the Company’s name change to “Nabis Holdings Inc.” (the “Name Change”) and continuance into the province of British Columbia (the “Continuation”) will be May 29, 2019.  The Company’s Canadian Securities Exchange (“CSE”) ticker symbol NAB will remain unchanged. 

Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P), dba Innovative Properties Inc., is a Canadian investment company pursuing interests in high-quality cash-flow assets in real property, securities, cryptocurrency and all branches of the cannabis sector. The company's focus on strategic revenue generation, EBITDA and growth is enshrined in its moto, "One team. One goal," and is reflected in its name: "Na bis," which is defined as, "repeat performance" or "encore."


While the Nabis' targets span numerous industries, the company aims to establish an Anchor Investment Portfolio primarily through the acquisition of majority interests in high quality U.S. cannabis assets and brands that have achieved cash flow. The company will then employ a hands-on approach to assist the investee in implementing standards and consistency to enhance their operations.

Criteria for investment targets are as follows:

  • Positive EBITDA, vertically integrated operators in limited license states with large addressable markets
  • Emphasis on operations that add material EBITDA within 12 months with enhanced access to capital and Nabis' value add approach on operations and brand consistency
  • Identifying proven operators with good expertise to add value to a consolidation strategy
  • Focused on MSOs (Multi-state Operators) with strong brand traction
  • Pharma grade cultivation, extraction, dispensaries and other addressable operations

Current Endeavors

Nabis has completed investments in five Michigan properties with Cannabis provisioning, processing and cultivation licenses. The Company has also entered into binding Letters of Intent ("LOI") to invest in vertically integrated assets in Michigan, Arizona and Washington State. The company's goal is to be invested in four to five additional states in the coming months.

Arizona – LOI to acquire full control of Organica Patient Group Inc. ("OPG") and RDF Management Group. OPG is a fully integrated medical marijuana business licensed under the provisions of the Arizona Medical Marijuana Act. Its assets include the Chino Valley MMJ Dispensary and fully established Patient Group, which since 2012 has operated as "Organica Patient Group" in Chino Valley. OPG also operates a 26,000-square-foot indoor cultivation and processing center along with a 56,600-square-foot greenhouse in Prescott Valley; has its own branded products and wholesale operations which includes distribution to more than 25% of the dispensaries in Arizona; and has exclusive manufacturing and licensing agreements with Fire Brand, Gas Extracts and Donuts Concentrate products distributed within Arizona.

Michigan – LOIs to invest in multiple strategically located properties that have or are eligible for municipal approvals for provisioning centers in Michigan. The company is currently evaluating 10 to 15 additional municipally approved locations in Michigan that would substantially increase the company's overall presence in the U.S. cannabis space.

Washington State – LOI to purchase assets from PDT Technologies LLC, including extraction and production equipment and rights to lease the current production facility in Port Townsend, Wash. The LOI includes licensing rights to produce Chong's Choice Brand CO2 Vape Cartridges, one of the leading and most recognizable brands in the cannabis space. Expansion plans include construction of a new ISO designed extraction clean room and GMP lab facility with new, highly specialized equipment with two extraction lines. The facility could produce up to 20,500 kg of cannabis concentrate on an annual basis.

Hivemind Refinery – LOI to invest in a 70% interest of Hivemind Refinery, an established line of CBD-based wellness products in the United States. The investment into Hivemind expands Nabis' investment portfolio to CBD edibles, water, drops, lotions, and other CBD wellness products across the spectrum. Nabis anticipates Hivemind will be a premium consumer CBD line to be distributed across the U.S. and Canada and will focus on products utilizing locally grown, premium CBD along with unique formulations and delivery systems.

Bloombox – binding term sheet with Momentum Ideas Co. to acquire certain assets used and marketed under the brand "Bloombox," a leading intelligent retail cannabis software platform that includes the Bloombox Software and data platform. The acquisition of Bloombox will create a dominating presence in the U.S. cannabis market, featuring an integrated ecosystem of modern, next-generation cannabis technology. Bloombox is one of the world's first standards-based cannabis software systems, enabling frictionless integration with nearly any business system or regulatory body.

Proven Management Team

CEO and Director Shay Shnet has over 20 years of experience in business and was most recently a founding partner and vice president of operations of MPX Bioceutical (CSE: MPX). While at MPX, Shnet focused on the North American cannabis space and helped build the company's portfolio of international cannabis assets. He is highly skilled in finding unique opportunities and has been directly involved with the development, branding, importing, consumer packaging and distribution of a wide variety of product lines.

President Mark Krytiuk is a very successful cannabis operator and was a founding partner of MPX. As the vice president of grow operations of MPX, he oversaw the production of medical marijuana and pharma-grade products across North America. He has been directly involved in overseeing the rapid expansion and buildout of nine facilities in three countries with budgets ranging up to $30 million. Krytiuk's experience includes consulting and working with customers to develop individual requirements for indoor and outdoor cannabis cultivation while working with federal regulators and licensing bodies to ensure compliance.

Nabis Holdings (OTC: INNPF), closed the day's trading session at $0.45311, up 2.28%, on 136,391 volume with 72 trades. The average volume for the last 3 months is 185,429 and the stock's 52-week low/high is $0.392/$0.791.

Recent News

QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX-V: QMC) (FSE: 3LQ)

The QualityStocks Daily Newsletter would like to spotlight QMC Quantum Minerals Corp. (QMCQF).

QMC Quantum Minerals (TSX.V: QMC) (OTC: QMCQF) (FSE: 3LQ), a British Columbia-based company engaged in the business of acquisition, exploration and development of natural resource properties, is advancing toward potential commercial production of lithium at its Irgon Dike through the ongoing development of a NI 43-101-compliant resource estimate.

QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX-V: QMC) (FSE: 3LQ) is a British Columbia based company engaged in the business of acquisition, exploration and development of natural resource properties. QMC’s focus is on creating shareholder value through strategic acquisition and development of high quality lithium, silver, gold, nickel, copper and zinc prospects.

QMC’s current properties are in the Canadian province of Manitoba, one of Canada’s most productive, centrally located mining regions. These resources include the Irgon Lithium Mine project and two Volcanic Massive Sulphide (“VMS”) properties – the Rocky Lake and Rocky-Namew known collectively as the Namew Lake District Project – which contain base metal-rich mineral deposits. Excellent access and well-developed mining infrastructure to the company’s wholly-owned Irgon Lithium Mine Project offers significant value and ramps up the near-term production schedule, putting QMC in a position to take advantage of rising lithium prices.

The region’s historic resource estimate of lithium is well documented in a 1956 Assessment Report developed by a previous owner, Lithium Corporation of Canada Ltd. The project’s historical resource estimate of 1.2 million tons grading 1.51% lithium-oxide over a strike length of 365 meters and to a depth of 213 meters is being updated by QMC through a detailed channel sampling and subsequent drill program.

North Face Software Ltd. recently created an interactive 3-D model of the Irgon Dike utilizing all historical data derived from past drilling and underground work. The 3-D model clearly demonstrates that exploration and underground development has only taken place on the central portion of the dike, leaving significant potential to quickly increase tonnage.

The company’s latest assay results, obtained from 144 channel samples at QMC’s Irgon Lithium Mine Project, provided encouraging and positive results that compare favorably with the historic assays. QMC has received a drill permit from the Sustainable Development Office of the Manitoba government and is in the process of requesting and assessing bids from drilling contractors. The company plans to begin a 2,000-meter drill program to confirm the historic lithium oxide assay results documented in the historic 1953-54 drill program.

QMC’s experienced leadership team includes specialists in mineral exploration, geology, engineering, new business development, marketing and investor relations. The company’s team of qualified advisors includes consultant Bruce E. Goad, P.Geo., who has 40 years of experience in mineral exploration in Canada, Argentina, Asia and Africa. As a Qualified Person, Goad has worked on numerous deposit styles including rare element pegmatites, porphyry, banded iron formation (BIF) gold deposits, skarn, greisens,  and VMS. He has a wide and varied skill set which includes precious, base, industrial and rare metal projects with a sharp focus on gold exploration. Goad is the author of several scholarly publications on pegmatite granites of the southeastern Manitoba region.

The market for lithium has surged over the past three years with prices per metric ton tripling. The world’s rising demand for portable power can easily been seen in the electric vehicle and mobile device industries – both of which use lithium-based, renewable batteries as a power resource. QMC’s high potential prospects and experienced management team, both in geology and corporate finance, put QMC and its shareholders in an excellent position to take advantage of the lithium, precious and base metals markets.

QMC Quantum Minerals Corp. (QMCQF), closed the day's trading session at $0.158875, up 1.39%, on 23,000 volume with 11 trades. The average volume for the last 3 months is 53,378 and the stock's 52-week low/high is $0.1155/$0.4607.

Recent News

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Growing demand for CBD is increasing pressure on companies that provide key cultivation equipment and industry supplies. As part of its commitment to build a large and well-supplied sales channel, hydroponic supplier Sugarmade Inc. (OTCQB: SGMD) (SGMD Profile) is in the process of making acquisition of companies that supply the hemp industry.

Sugarmade, Inc. (SGMD), one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space, is a product and brand marketing company investing in products and brands with disruptive potential. Sugarmade’s brands include:;; and BudLife. Headquartered in Monrovia, California, a city within Los Angeles county, Sugarmade has various business operations in diverse marketplaces including packaging and paper goods for various industries, agricultural supplies.

Sugarmade has expanded into the European hydroponics supply market with a growing base of orders taken through Amazon UK. Over the past few financial quarters, Sugarmade has seen revenue growth patterns expand geographically. As recently as mid-2017, the majority of hydroponic-related revenue growth was seen from California and other West Coast marketplaces, however growth is becoming more geographically dispersed among U.S. states where legalization has eased restriction. This movement into the United Kingdom further expands the base of geographic growth areas for Sugarmade.

Sugarmade recently launched a new corporate initiative in the booming industrial hemp and CBD, committing up to $1 million in capital over the next 12 months to invest in Hempistry, Inc., a privately held Nevada corporation. Hempistry has begun planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 23,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3 percent of THC, the psychoactive ingredient found in cannabis. The U.S. hemp industry is expected to produce well over $1 billion in revenues in 2018, with a compound annual growth rate of 14 percent through 2022, according to the Hemp Business Journal.

Demand for industrial hemp and products derived from hemp is soaring, with no let-up in sight, which the company sees as a “tremendous opportunity to become a supplier to this fast-growing sector,” said Chairman and CEO Jimmy Chan, who is also an advisor and minority shareholder of Hempistry.

Sugarmade’s investment into the market for high-CBD hemp is expected to be highly accretive for common shareholders in two ways. First, Sugarmade’s investment will be in the form of common shares in Hempistry allowing Sugarmade common shareholders to possibly benefit from any future initial public offering of Hempistry. Second, Sugarmade is expected to sign a supply agreement with Hempistry for cultivation supplies, which would be additive to corporate revenues.

Sugarmade has also completed a master market agreement with industry leader BizRight Hydroponics, Inc., a leading marketer and manufacturer of cannabis and hydroponic growth supplies, which offers a range of hydroponics-related products including: HPS grow lights, electronic ballasts, HPS bulbs, nutrient mixes, environmental control products, pH measurement and calibration solutions and storage products. BizRight operates the website and other e-commerce properties and sells various products to distributors and retailers. BizRight is expected to produce in excess of $30 million in revenues during 2017, with substantial growth expected for 2018.

Sugarmade division, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30-40 percent of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.


CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Arman Tabatabaei serves as operations consultant, providing high-level, day-to-day strategic guidance and tactical operational supervision for all aspects of the corporation’s business. He is an expert at data collection and analysis relative to resource management, risk forecasting and profit and loss management.

Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base. 6

Sugarmade, Inc. (SGMD), closed the day's trading session at $0.0318, up 4.61%, on 2,613,594 volume with 260 trades. The average volume for the last 3 months is 1,319,332 and the stock's 52-week low/high is $0.028/$0.1975.

Recent News

Geyser Brands Inc. (TSX.V: GYSR)

The QualityStocks Daily Newsletter would like to spotlight Geyser Brands Inc. (TSX.V: GYSR).

Geyser Brands Inc. (TSXV:GYSR) ("Geyser Brands" or the "Company") is pleased to announce that, further to the Company's news release dated February 11, 2019, the Company has entered into a definitive agreement (the "Agreement") in respect of the previously announced acquisition of Solace Management Group Inc. ("Solace"), a private corporation existing under the laws of British Columbia (the "Proposed Transaction").

Geyser Brands Inc. (TSX.V: GYSR) is a consumer healthcare company that builds and markets some of the world's most loved cannabis products and brands in the nutraceutical, cosmetics, food and beverage and pet sectors. Using its proprietary nanotechnology formulation, the company delivers creams, beverages, baked goods and tincture formulations with superior bioavailability and water solubility.

NanoFusion Technology

The efficacy of most hemp?products is restricted as the insoluble nature of the molecules prevents most of the product from permeating the skin or entering the body system. Geyser Brands solves this insolubility problem with an advanced delivery system that quickly and efficiently transports therapeutic agents directly to the bloodstream for maximum absorbency.

Made with all-natural materials, NanoFusion technology offers an array of advantages: enhances penetration for deeper skin penetration; improves the transport of active ingredients for site-specific targeting; delivers active ingredients across cell membranes for release within the cell; provides longer shelf-life and stability of molecules.


Geyser Brands operates a 7,000-square-foot facility in Port Coquitlam, British Columbia, where its initial cannabis cultivation generated the first revenues out of the company's cultivation license granted in October 2018. Geyser Brands is approved as a licensed producer in compliance with Health Canada standards, which allows the company to pursue its processing and sales license. Obtaining this license will enable the company to extend its products and brands into the regulated Canadian cannabis market and directly to the consumer medical market.

Geyser Brands's integrated production chain and formulation lab develops innovative products using high-quality hemp and CBD for healthy lifestyle brands while its R&D lab produces product formulations designed to enhance bio-availability of hemp and CBD and shelf stability while maintaining all-natural ingredients and ensuring premium quality.

Geyser Brands will continue to seek opportunities to invest into the research and development of unique high-quality proprietary strains and technologies that target specific health-related conditions such as pain and inflammation reduction, insomnia, digestive issues and other commonly known ailments.

Growing Portfolio

Among the brand formulations in Geyser Brand's portfolio are:

  • Apothecary all-natural Hemp Terpene Pain Cream with optimal skin permeation
  • Prohibition Cold Brew Mocha designed with water soluble hemp molecules
  • Apothecary health products created to deliver fast-acting and high bioavailability in a spray formulation
  • Baked hemp infused pet products, designed to alleviate anxiety and pain, created with NanoFusion for dosage control

Management Team

Since 2014, Geyser Brands' CEO and Co-Founder Andreas Thatcher has been a principal at Rhizome Group, an entertainment company focused on building media IP through creative and market development. He previously was a founding partner at Rhizome Capital LLC, a U.S.-based media?investment?company specializing in marketing and distribution financing, and worked in the Investment Banking industry in?London and Toronto. Thatcher holds a master's degree in economics.

CFO Barry McKnight obtained his bachelor's degree from the University of British Columbia and is a Chartered Professional Accountant and?Certified Management Accountant registered in British Columbia. McKnight has over 20 years of experience as the principal of Barry D. McKnight Inc. He formerly was also a director of Indigo Sky Capital Corp. and has been the CFO and a director of the Company since 2016 and Corporate?Secretary of the Company since 2017.

Geyser Brands's Co-Founder Brad Kersch brings a strong business background with over 20 years of experience in?successful startups and working?with Fortune 500 companies. He spent his early years in the advertising and?marketing field and went on to form Hyperware, a clothing?company that sold branded clothing to retailers across Canada?before selling to clothing giant Ocean Pacific (OP). Kersch?became the president of Shoreline Studios, Canada's largest and?oldest?studio for film and TV. In 2014 he started Solace Management Group, a hemp product company focused on pet, cosmeceutical, and nutraceutical markets. As of February 2019, Geyser Brands signed a non-binding LOI to acquire Solace Management. Upon completing the proposed Solace acquisition, Geyser Brands intends to launch into the execution phase of its plan — to take its brands global through retail and digital direct-to-consumer experiences, launching its hemp-infused cannabis brands and products in the U.S., European Union, and Asia, and its CBD-infused line of products in jurisdictions where the therapeutic ingredient is legal.

Kuldip Gill, head of Geyser Brands' R&D program, has more than 35 years of experience in the cannabis industry. Gill built the largest manufacturing facility?in the lower mainland in Surrey, British Columbia, complete with R&D, analytical and quality control labs approved by both the FDA and Health Canada. He has to date created over 3,500 formulas, most notably Lakota pain relief gel. Gill's experience and proven track record is evident in the strongly marketable formulations he has developed and sold worldwide.

Geyser Brands Inc. (TSX.V: GYSR), closed the day's trading session at $0.73, even for the day, on 15 volume with 1 trade. The average volume for the last 3 months is 8,376 and the stock's 52-week low/high is $0.61/$0.85.

Recent News

Redfund Capital Corp. (CSE: LOAN) (OTCQB: PNNRF) (FF: O3X4)

The QualityStocks Daily Newsletter would like to spotlight Redfund Capital Corp. (PNNRF).

Redfund Capital Corp. (CSE: LOAN) (OTCQB: PNNRF) (Frankfurt: O3X4) was featured today in the 420 with CNW by CannabisNewsWire. Banking associations from all the 50 states across the U.S. have written a letter to the Senate Banking Committee to pass and advance the bipartisan bill before it seeking to protect financial institutions from federal penalties for doing business with licensed marijuana businesses.

Redfund Capital Corp. (CSE: LOAN) (OTCQB: PNNRF) (FF: O3X4) is a merchant bank focused on providing debt and equity funding in the mid to late stages of a target company’s development and for technologies that are developed and validated by revenues. Redfund’s current focus is on medical cannabis, hemp and cannabidiol (CBD) related and healthcare-related companies.

As the first medical cannabis incubator and accelerator financing medical cannabis, CBD and hemp companies through a debt facility, Redfund is effectively bridging finance gaps and helping revenue-producing medical cannabis-related companies grow and build their valuations without prematurely diluting their equity.

The central components of the company’s business strategy are:

  • Establishing the foundation of a loan portfolio that generates revenues through monthly interest income from loans to cover all general and administrative expenses related to day-to-day operations.
  • Growing shareholder value by converting all or part of loans and warrants into equity in portfolio clients as clients build their valuations by entering the public markets or becoming the high-priced targets of larger entities.

Redfund was designed by bankers and entrepreneurs possessing years of experience in business, consulting, capital markets, corporate finance and healthcare services. The company is actively looking beyond borders and creating global companies that have strong fundamentals and are ready to expand.

Redfund’s investments are deployed to companies that have demonstrated success in their business but need a capital bridge in order to expand. Redfund’s team of professionals vet every project and analyzes each prospective client’s financials and business plans. Once a project is approved, Redfund’s legal team carefully scrutinizes the collateral used to securitize the individual loans.

The strategy employed by Redfund includes:

  • Diversifying investments in Canada and other countries
  • Building an international footprint with established national leaders
  • Funding new drug delivery systems and helping nutraceuticals become mainstream drugs
  • Introducing companies to Canada as a viable option for public listings
  • Becoming a premier go-to lender for established companies

The company’s revenue sources include:

  • Interest-bearing debt instruments with asset-backed collateral to securitize loans
  • Equity kicker of warrants coverage on original loan
  • Conversion ability of loan in its entirety
  • Advisory fees from contracts for consulting on growth strategies
  • Right of first refusal on future financing in each company funded

Redfund Capital Corp. (OTCQB: PNNRF), closed the day's trading session at $0.09119, even for the day, on 999 volume. The average volume for the last 3 months is 538 and the stock's 52-week low/high is $0.09/$0.505.

Recent News

INmune Bio Inc. (NASDAQ: INMB)

The QualityStocks Daily Newsletter would like to spotlight INmune Bio Inc. (NASDAQ: INMB).

INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that David Moss, the Company’s co-founder and CFO, will present at the 9th Annual LD Micro Invitational. The event is being held at the Luxe Sunset Boulevard Hotel in Bel-Air, California, on June 4-5, 2019.

INmune Bio Inc. (NASDAQ: INMB) is a diversified clinical-stage immunology company developing novel therapies that target distinct parts of a patient's innate immune system to fight disease. Drug candidates INKmune™ and INB03 may be used to treat cancer while XPro1595 targets neuroinflammation as a cause of Alzheimer's disease. INmune Bio's product platforms utilize a precision therapy approach to promote the body's innate immune response to treat unsolved problems in medicine.

INmune Bio is the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on The Nasdaq Capital Market. The company also received a "Part the Cloud" award from the Alzheimer's Association in 2018 which included a $1 million grant to advance INmune Bio's XPro1595 drug candidate.

INmune Bio's product pipeline targets three segments of concern:

  • Alzheimer's disease/dementia claims 5.5 million patients in the United States. INmune Bio views Alzheimer's as an immunologic disease which changes the drug discovery process, changes the way clinical trials are designed, and may provide hope for patients and caregivers.
  • Cancer residual disease which is expected to generate more than 1.7 million new cases yearly with an estimated 609,640 fatalities. INMB believe that converting resting Natural Killer ("NK") cells to primed NK cells, which kill cancerous cells on contact, is an important therapeutic strategy to help clear residual disease.
  • Resistance to immunotherapy. By preventing the proliferation and function of cells that resist immunotherapy, patients should have a stronger immune response to cancer cells and may respond better to other cancer treatments including immunotherapy and live longer.

INmune Bio Drug Candidates and Clinical Programs

INKmune is a biologic delivery system that primes a patient's resting NK cells to kill cancer. INKmune targets residual disease for patients that have completed initial cancer therapy (surgery, radiation and/or chemotherapy) and have a low burden of disease with a high risk of relapse.

In late 2019, INKmune will start enrolling patients in a phase I/II trial for women with relapsed refractory ovarian cancer. In many patients, cancer relapse after seemingly effective cancer therapy is due to a failure of the patients own NK cells to eliminate minimal residual disease ("MRD").

Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells' ability to eliminate residual disease.

INB03 is a checkpoint inhibitor that targets myeloid derived suppressor cells ("MDSC") which can produce an immunosuppressive shield that prevents a patient's own immune system from attacking the cancer. INmune Bio is currently completing a monotherapy INB03 phase I trial in patients with advanced solid tumors. The INB03 program will transition into a combination therapy clinical program in the summer of 2019 to prepare for a phase II trial in patients resistant to checkpoint inhibitors due to increased MDSC.

Treatment with INB03 should eliminate MDSC in the tumor microenvironment to allow checkpoint inhibitors to be therapeutically effective.

XPro1595 targets the microglial immune cells of the brain that are activated in many Alzheimer's disease patients. These microglial cells are a cause of neuroinflammation that can kill nerve cells and promote synaptic dysfunction – the cause of dementia in Alzheimer's.

The three-month, phase I trial is expected to enroll 18 patients in summer of 2019. It is designed to measure traditional and novel biomarkers of inflammation in patients with mild to moderate Alzheimer's disease who have neuroinflammation. The trial is supported by a $1 million "Part the Cloud" grant from the Alzheimer's Association. Inflammation, especially chronic inflammation, is being recognized as an important part of the pathology of many diseases including cancer and Alzheimer's disease.


Dr. RJ Tesi, M.D., INmune Bio co-founder, CEO and acting chief medical officer, has been a licensed physician since 1982 and a Fellow of the American College of Surgery since 1991. He received his medical degree from Washington University School of Medicine in 1982 and has served many roles in several development-stage biotech companies focused on treatment of neurodegenerative diseases, hematologic malignancies, and other inflammatory diseases.

CFO David J. Moss co-founder, has been with the company since its formation in September 2015. He holds an MBA from Rice University and a bachelor's degree in economics from the University of California, San Diego. Moss has founded, funded and taken public various companies in a variety of industries since 1995.

Mark Lowdell, Ph.D. co-founder, has served as the chief scientific officer and chief manufacturing officer at INmune Bio since the company's formation. He is a professor of cell and tissue therapy at University College London where he has led a translational immunotherapy group since 1994. He has also been a director of cellular therapy at the Royal Free London NHS Foundation Trust. He received his Ph.D. in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.

Christopher J. Barnum is director of neuroscience at INmune Bio. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academic and industry. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker-directed approach. Barnum's research has been supported by the NIH, the Michael J. Fox Foundation, and the Alzheimer's Association. He received his Ph.D. in neuroscience from Binghamton University.

INmune Bio Inc. (OTC: INMB), closed the day's trading session at $10.59, off by 1.95%, on 8,434 volume with 76 trades. The average volume for the last 3 months is 18,106 and the stock's 52-week low/high is $7.00/$11.50.

Recent News

TransCanna Holdings Inc. (CSE: TCAN)

The QualityStocks Daily Newsletter would like to spotlight TransCanna Holdings Inc. (CSE: TCAN).

TransCanna Holdings (CSE: TCAN) (FSE: TH8) this morning announced that SolDaze, a company TransCanna recently entered into a non-binding Letter of Intent (“LOI”) with to acquire its business and assets, has started receiving pre-orders for its new Spicy Mango line of cannabis-infused mango snacks. To view the full press release, visit:

TransCanna Holdings Inc. (CSE: TCAN) through its subsidiaries specializes in assisting clients who are cannabis farmers and manufacturers get recognized by end consumers who in turn purchase their products. TransCanna offers or will be offering services to support almost every aspect of the cannabis-related eco-system; from branding and design, to transportation and distribution, to marketing and sales.

California’s legalized adult-use recreational marijuana market opened for business January 1, 2018. The state’s Bureau of Cannabis Control is responsible for regulating all commercial activities in the state including cultivation, distribution and transportation. Moving cannabis products in the California marketplace is extremely challenging due to municipal and state laws and regulations, which can differ among cities and counties. Since cannabis remains illegal under federal law, Department of Transportation regulated companies are barred from participating in the market, which means companies looking to excel in the sector must hold a state-issued distributor license from the Bureau of Cannabis Control.

TransCanna has already entered into an Intellectual Property Rights and Royalty Agreement for the Track & Trace software platform required by the state of California. TCM Distribution, the operating company managed by TransCanna, has received a transportation and distribution permit from the city of Adelanto and a temporary transportation and distribution permit from the state of California. TransCanna has also executed a land lease to build a 10,000-square-foot transportation and distribution facility in Adelanto.

TransCanna is strategically creating a distribution network throughout California that places its facilities no further than a three-hour drive from most any client. The company is in the process of leasing or purchasing properly licensed and permitted warehouses strategically located throughout California along with new secure trucks, sprinter vans and/or armored vehicles.

TransCanna plans to create its own portfolio of branded products for the cannabis and hemp sectors. The company’s management team intends to translate the skills, knowledge and experience gained from a combined 60 years of branding and marketing experience in the music, professional sports and alcohol industries into TransCanna and the cannabis industry.

As part of the “TransCanna Way,” the company intends to manage most aspects of the supply chain from upper end procurement, branding, transportation and distribution, to marketing and sales.

Leading TransCanna as its CEO and chairman is James Pakulis, who has three decades of experience working with public and private entrepreneurial companies in a variety of emerging and high-growth sectors. He is formerly the president and a director of Lifestyle Delivery Systems Inc. (CSE: LDS) (OTCQB: LDSYF), a vertically integrated cannabis-related entity operating in California. Pakulis was chairman and CEO of General Cannabis Inc. which from 2010 to 2012 owned WeedMaps. Pakulis oversaw the company’s growth from zero to over $16 million in annual revenue in less than 24 months.

The company’s strategic advisors include individuals with extensive experience in branding, marketing, sales, distribution, production and supply chain management.

For additional information, call: (604) 609-6199

TransCanna Holdings Inc. (CSE: TCAN), closed the day's trading session at $5.85, off by 5.80%, on 51,330 volume with 78 trades. The average volume for the last 3 months is 163,240 and the stock's 52-week low/high is $0.77/$7.79.

Recent News

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF)

The QualityStocks Daily Newsletter would like to spotlight Canopy Rivers Inc. (RIV) (CNPOF).

Les Serres Vert Cannabis Inc. ("Vert Mirabel"), a subsidiary of Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) ("Canopy Growth") and a portfolio company of Canopy Rivers Inc. (TSXV: RIV) (OTC: CNPOF) ("Canopy Rivers") has received its final cultivation license from Health Canada. Also today, the company was announced that it would be hosting its analyst and investor day from 1:00 p.m. to 5:00 p.m. ET, May 28. The event was webcast live and all interested parties were invited to join. The webcast is available on Canopy Rivers' website at Additionally, the company was highlighted in a publication from, examining how it’s become tough to ignore the cannabis story.

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) is the venture capital investment platform of Canopy Growth Corporation (TSX:WEED, NYSE:CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

  • Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
  • CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
  • Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
  • James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
  • LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
  • PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
  • Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
  • Solo Growth (TSXV:ALZ) is a new cannabis retail concept that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Solo Liquor Stores Ltd., a leading Canadian liquor retailer. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy.
  • Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
  • TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
  • Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Canopy Rivers Inc. (TSX.V: RIV), closed the day's trading session at $4.53, off by 0.44%, on 462,176 volume with 1,317 trades. The average volume for the last 3 months is 502,204 and the stock's 52-week low/high is $2.40/$11.82.

Recent News

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Gene therapy could potentially advance the creation and delivery of effective cancer treatments in the years to come. Various companies are leading the way, and pioneers such as Genprex Inc. (NASDAQ: GNPX) are pushing for the introduction of innovative and targeted therapies that have the potential to help patients with various malignancies.

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed the day's trading session at $1.60, off by 0.16%, on 23,271 volume with 64 trades. The average volume for the last 3 months is 50,244 and the stock's 52-week low/high is $0.95/$12.24.

Recent News

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

The QualityStocks Daily Newsletter would like to spotlight Wildflower Brands Inc. (WLDFF).

Wildflower Brands Inc. (CSE: SUN, OTC: WLDFF) (the “Company” or “Wildflower”) announces that it has executed a share purchase agreement (the “Definitive Agreement”) with City Cannabis Corp. (“City Cannabis”) to acquire all of the issued and outstanding shares of City Cannabis (the “Acquisition”). Also today, NetworkNewsWire released a report on the company detailing how WLDFF was recently featured in an article on Miss Grass. Madison Margolin, the author of the article, ‘HIGH CITY GUIDE: Los Angeles,’ mentions one of LA’s monthly pop-up events, Zen & Kush, and recommends Wildflower's CBD vaporizer to enjoy at the booze-free event. The vaporizer’s blend of lavender and peppermint leaves customers with an icy cool relief from aches and pains. It is available for purchase on the Miss Grass website for $60.00 ( To view the full article, visit:

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is a public cannabis company developing and designing brands that focus on plant-based wellness and health products. Wildflower markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States and in legal cannabis markets in accordance with regulations marketing its THC and CBD products.

Headquartered in Vancouver, British Columbia, Canada, Wildflower employs a unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. First launched in 2012 as a private company with a cannabis-focused brand, Wildflower went public in 2014 and has since reached numerous significant milestones in its drive to create brands that work in synergy toward becoming a global wellness brand leader.

Gathered within the growing family of Wildflower brands are the following entities:

  • Wildflower Wellness is known for its reputable brand, uncompromising quality and mission to connect people with the healing power of plants. Wildflower Wellness offers CBD vaporizers, capsules, tinctures, soaps and topicals that are backed by a 100 percent satisfaction guarantee. Wildflower Wellness offers a full lineup of full spectrum CBD extract infused products made in the U.S. in Wildflower’s GMP facilities which are always third-party lab tested for quality assurance and accurate labeling.
  • King Extracts is a California-based company focused on cannabis technology and delivery systems. The King Recharge is a discreet, 97mm small, rechargeable vaporizer with a sleek pocket-sized charging and storage case. King concentrates are clean and sophisticated blends made from CO2 extractions that are fractionally distilled for clarity and purity with proprietary terpenes blended in to deliver a robust, full-flavor profile. King products are available at 26 select, regulated retail dispensaries in California.
  • Exclusive is a dispensary of high-quality cannabis products and accessories serving the city of Los Angeles, California. The company enjoys a close association with select hospital oncology departments and community programs.

Using the slogan “Plants Heal,” Wildflower’s distribution network in the U.S. includes 200+ retailers in Washington state and 20+ retailers in New York City. Wildflower has also partnered with Retail Worx to establish shop-in-shop retail locations in the heart of New York City which pairs nicely with the introduction of Wildflower into existing Bridges General’s stores in New York City and San Francisco. Through this partnership with Retail Worx, Wildflower by Bridges General stores will have exclusive product offerings in addition to the full lineup of existing Wildflower Wellness CBD products. Distribution in other U.S. markets includes 80+ wellness and healthcare practitioners with a total distribution of over 300 stores nationwide.

Wildflower holds 14 California cannabis licenses that cover recreational and medical cannabis cultivation, manufacturing, distribution and retail/delivery in the jurisdictions of California state and the city of Los Angeles. Opportunities to activate these licenses creates the phenomenal potential of driving significant revenues while minimizing risk. Expansion plans into Canada are underway with discussions centered on retail acquisitions and Wildflower launching into over-the-counter market with its CBD product line. Global expansion is a key part of Wildflower’s strategy with initial plans aimed at specific international markets where regulatory hurdles are less restrictive.

In December 2018, Wildflower began on-demand, legal and licensed cannabis delivery services to adult consumers in the Los Angeles area and has hired dozens of full-time delivery drivers to accommodate this unmet need. Wildflower has partnered with leading technology and logistics company to help route deliveries efficiently, manage inventory and comply with California law. Providing legal, licensed delivery services helps to ensure that all adults including those with mobility challenges and limited access to transportation services can purchase high quality, legal cannabis products.

Wildflower’s direct-to-consumer online store sales have shown an organic growth. The Company recently achieved over 300 percent growth in online sales since January 2018 with annualized revenues exceeding $1 million for online sales only, marking the ninth consecutive quarter of increased revenue.

Core Team

William MacLean is the founder and CEO of Wildflower Brands Inc. His involvement in all aspects of the business from product R&D to manufacturing setup has led the Company to its current success. MacLean is a seasoned sales professional with over 20 years of experience in various industries from advertising and marketing to medical sales. While in the advertising and marketing space, his clients included major brands including: Bell, Remax, BC Hydro, and Royal Bank.

CFO Stephen Pearce is a director and officer of a number of public companies in the resource sector. His professional experience as a practicing attorney is primarily in corporate and securities work. Pearce’s academic background includes an honors bachelor’s degree in economics from York University, in which he focused specifically on corporate finance. Pearce obtained a law degree from the University of British Columbia.

Alfred Kee, COO, is a business technology leader with over 15 years of experience in building high performing teams at small startups to large enterprises. With foundations in running large scale business critical technology and user experience product management mindset, Kee excels at guiding teams to deliver business value with agility. His knowledge and experience were honed while working with Electronic Arts, KPMG, CenturyLink, Cisco and Apple, as well as a string of successful startups. Lee brings a global perspective having lived and worked through parts of the U.S., Canada, Europe and Asia.

Creative Director Amy Yamamura is a founding member of Wildflower and has been a driving force behind the Company from the start, creating the Wildflower brand. After receiving a bachelor’s degree in communications from Boston University, Yamamura returned to Tokyo to develop her career in TV as an international business correspondent coordinating collaborative projects between top creators around the world and corporations. Yamamura’s unique experience in working closely with successful Japanese brands like UNIQLO has given her exceptional eyes for branding a company.

Wildflower Brands Inc. (WLDFF), closed the day's trading session at $0.490845, off by 0.76%, on 23,418 volume with 21 trades. The average volume for the last 3 months is 22,937 and the stock's 52-week low/high is $0.009/$1.129.

Recent News (CIIX)

The QualityStocks Daily Newsletter would like to spotlight (CIIX)., Inc. (OTCQB: CIIX), an established financial news and investment portal for the global Chinese-speaking community, today announced that it will be presenting at the 9th Annual LD Micro Invitational, to be held June 4–5, 2019, at the Luxe Sunset in Bel-Air, California.

Founded in 1999, (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website,, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site,, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. (CIIX), closed the day's trading session at $0.43, off by 2.69%, on 17,854 volume with 17 trades. The average volume for the last 3 months is 59,754 and the stock's 52-week low/high is $0.365/$1.25.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global Corporation (OTCQB: SHRG) is utilizing its Blue Ocean Strategy in the direct-selling industry as it prepares to follow up on success in the United States with entry into Canada. The company plans to build on its recent success through its Elepreneur subsidiary and an expanded focus on additional international markets.

Sharing Services Global Corporation (SHRG), headquartered in Plano, Texas, is a diversified holdings company focused on reshaping how entrepreneurs succeed today. Sharing Services Inc. owns, operates or controls an interest in a variety of companies specializing in the direct selling industry that either sell products to the consumer directly through independent representatives or offer services that range from health and wellness, energy, technology, insurance services, training, media and travel benefits. SHRG has created the “Blue Ocean Strategy,” which melds three keys together to implement the company’s vision. These keys include elevating home-based entrepreneurs, known as “Elepreneurs,” utilizing the direct selling channel to generate 100 percent organic growth.

Sharing Services Inc. subsidiaries include:

  • A growing international network of home-based entrepreneurs, called “Elepreneurs”
  • Growing selection of health and wellness products dedicated to elevating the well-being of all people
  • Insurance from auto, home and life to health benefit discounts and health insurance that help families elevate their options
  • Wholesale travel and payment programs with travel concierges that empower more families to go on vacation
  • Live seminars and training events – from Vacationars™ to EduTainment – that elevate the skills and knowledge of entrepreneurs around the world
  • Unique compensation and reward programs crafted to help entrepreneurs elevate their health, wealth and happiness

Sharing Services recently expanded its corporate footprint by moving to a 10,000 square foot facility in Plano, Texas, that offers room to expand as the company grows and its subsidiaries flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

“The opportunity to expand to the rest of this new building over the course of the next six to 12 months ensures we won’t have to move again anytime soon,” Sharing Services Inc. Chairman Robert Oblon said. “We are on track for very significant growth here in the U.S., as well as upcoming international expansion, so this move is in preparation for what’s in front of us.”

The company recently signed a joint venture agreement with Health Wealth & Happiness Limited (“HWH”) to expand its “Elepreneurs” brand and market its products throughout Asia. The newly formed company will be named “Elepreneurs Asia Limited” and will have marketing and sales rights to China, Hong Kong, Macau, South Korea, Japan, Taiwan, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam and Papua, New Guinea. A soft launch of the Elepreneur program is scheduled sometime later in 2018 with HWH CEP Fai Chan and his team leading the effort. Formed in Hong Kong, Health Wealth & Happiness Limited is dedicated to working with visionary partners like Sharing Services Inc. to deliver the best products and services to improve the well-being of consumers.

Nearly 1,000 people attended Sharing Services Global Corporation ’s first “Elepreneur Happiness Convention,” held March 2-3, 2018, in Dallas, Texas. Attendees arrived from several countries including the U.S., Canada, Mexico, Singapore and Hong Kong. Keynote speakers included several internationally known motivational leaders – Shawn Achor, Sandra Yancey, John Fleming and Les Brown – who provided exceptional material and inspirational discussion points.

“The enthusiasm of our attendees and the early success that we are experiencing is incredible considering our growth has been 100 percent organic, with almost no marketing from the company,” Oblon said. “I’m speechless by the dedication of our Elepreneur leaders and their entire teams, as they share our incredible line of products that have helped so many people.”

Sharing Services and its management team plan to travel the U.S. to hold several mini conferences to expand on the messages presented at its Happiness Convention that focus on helping people become “healthier, happier and wealthier.” Details of the company’s aggressive global expansion initiatives are soon to be announced, Oblon said.

The law firm of Gardere Wynne Sewell LLP has been retained as outside corporate counsel for all general business matters. The Dallas-based law firm will represent Sharing Services Global Corporation , and its subsidiaries as the company utilizes the direct selling channel for a significant component of its overall growth strategy.

John “JT” Thatchwas appointed president and chief executive officer of Sharing Services Global Corporation , at a March 1, 2018, annual shareholder meeting. Thatch has successfully started, owned and operated several sized businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist Sharing Services Inc. as the company aims to expand and increase revenues.

Sharing Services Global Corporation (SHRG), closed the day's trading session at $0.17, off by 0.06%, on 100 volume with 1 trade. The average volume for the last 3 months is 23,141 and the stock's 52-week low/high is $0.15/$0.3944.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.